These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25039242)

  • 1. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study.
    Erdei A; Paragh G; Kovacs P; Karanyi Z; Berenyi E; Galuska L; Lenkey A; Szabados L; Gyory F; Ujhelyi B; Berta A; Boda J; Berta E; Bodor M; Gazdag A; Nagy EV
    Autoimmunity; 2014 Dec; 47(8):548-55. PubMed ID: 25039242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
    Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of disease activity in Graves' orbitopathy with different methods: comparison of (99m)Tc-DTPA and (99m)Tc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores.
    Galuska L; Leovey A; Szucs-Farkas Z; Szabados L; Garai I; Berta A; Balazs E; Varga J; Nagy EV
    Nucl Med Commun; 2005 May; 26(5):407-14. PubMed ID: 15838422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy.
    Ujhelyi B; Erdei A; Galuska L; Varga J; Szabados L; Balazs E; Bodor M; Cseke B; Karanyi Z; Leovey A; Mezosi E; Burman KD; Berta A; Nagy EV
    Thyroid; 2009 Apr; 19(4):375-80. PubMed ID: 19355827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
    Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
    Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
    Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
    Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
    Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
    Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
    Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
    Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
    Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
    Siderova M; Hristozov K; Tsukeva A
    Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset.
    Lantz M; Planck T; Asman P; Hallengren B
    Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):113-7. PubMed ID: 24554511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves' orbitopathy.
    Mitchell AL; Gan EH; Morris M; Johnson K; Neoh C; Dickinson AJ; Perros P; Pearce SH
    Clin Endocrinol (Oxf); 2013 Sep; 79(3):437-42. PubMed ID: 23320840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
    Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
    Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Graves' ophthalmopathy after percutaneous ethanol injection in a nontoxic thyroid nodule.
    Regalbuto C; Le Moli R; Muscia V; Russo M; Vigneri R; Pezzino V
    Thyroid; 2012 Feb; 22(2):210-3. PubMed ID: 22196093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.